These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24014294)

  • 1. TP53 aberrations in chronic lymphocytic leukemia.
    Trbusek M; Malcikova J
    Adv Exp Med Biol; 2013; 792():109-31. PubMed ID: 24014294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Tam CS; Stilgenbauer S
    Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
    Malcikova J; Pavlova S; Kozubik KS; Pospisilova S
    Hum Mutat; 2014 Jun; 35(6):663-71. PubMed ID: 24415659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
    Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
    Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
    Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
    Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
    Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 dysfunction in CLL: Implications for prognosis and treatment.
    Te Raa GD; Kater AP
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):90-99. PubMed ID: 27742075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.
    de Viron E; Michaux L; Put N; Bontemps F; Van Den Neste E
    Leuk Lymphoma; 2012 Aug; 53(8):1445-51. PubMed ID: 22280536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
    Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
    Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
    Shindiapina P; Brown JR; Danilov AV
    Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.
    Thornton PD; Gruszka-Westwood AM; Hamoudi RA; Atkinson S; Kaczmarek P; Morilla RM; Hilditch BL; A'Hern R; Matutes E; Catovsky D
    Hematol J; 2004; 5(1):47-54. PubMed ID: 14745430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
    Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
    te Raa GD; Moerland PD; Leeksma AC; Derks IA; Yigittop H; Laddach N; Loden-van Straaten M; Navrkalova V; Trbusek M; Luijks DM; Zenz T; Skowronska A; Hoogendoorn M; Stankovic T; van Oers MH; Eldering E; Kater AP
    Cell Death Dis; 2015 Aug; 6(8):e1852. PubMed ID: 26247737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat E; Dreger P
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
    Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding and managing ultra high-risk chronic lymphocytic leukemia.
    Stilgenbauer S; Zenz T
    Hematology Am Soc Hematol Educ Program; 2010; 2010():481-8. PubMed ID: 21239840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.